about
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasmsIncidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromesPatterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.Survival in multiple myeloma patients who develop second malignancies: a population-based cohort studyHistory of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.Blood donation and risk of polycythemia vera.Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.Survival in patients with familial and sporadic myeloproliferative neoplasms.Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.Self-reported fertility in long-term survivors of acute myeloid leukemia.Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.[High hemoglobin, not always polycythaemia vera. Weak evidence for the effect of venesection in other erythrocytoses].Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative NeoplasmsFamily history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based studySuicide in multiple myeloma and acute myeloid leukaemiaElevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphomaMRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored TreatmentCorrection: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myelomaStability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomaComprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myelomaAssociation of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple MyelomaIncidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in SwedenRisk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients
P50
Q34798105-4C70E415-43EE-48F8-A142-7C8511013BEBQ35023473-430AEE06-FD82-41AA-93A0-94A8BF56D559Q35032345-AA7B0108-0E7C-4B90-8647-93DF3B708521Q35112049-786CC867-E77D-4390-82B4-2B6C5700286EQ35112330-6E11D8D6-3BFD-403A-8680-14B955A580A5Q36157668-DAD35B48-36B4-46EE-AC45-1A476B8C7842Q37216305-92B77F3D-0AD1-4628-9CB9-AD70ECF33E90Q37580855-A69B12DD-6A34-4CD9-A031-76B4976B036BQ38246161-A0899F6C-3FFE-46F6-842E-6B85E5243C34Q40257930-618109A7-887D-4599-B2E3-454AFCE3AE6BQ40938601-55F24F81-9A5B-44B0-A899-61031C462849Q41190830-38F9F4AC-31A9-4495-938D-B8F5323DCB79Q42606483-665D6962-421A-407A-87DC-153723BC40B3Q43234217-0E9A999C-733A-4383-BC81-3422221F4DFFQ44183913-75EA5F30-1275-42FD-ADEC-07B108B3D1D7Q47118240-03C1E938-4A01-43C4-B0FB-28D98C5668C1Q50042051-8B13849A-E644-49C6-B3E6-D9E5622C0F99Q52657272-C53FB80E-57CA-4CC9-B6A1-15EE56924529Q54452867-374E9957-8C01-4921-92A0-3C303925242BQ61860414-3AA4A008-A53D-40E0-A84F-4FB126190F20Q61860439-904DB75E-A753-4C15-B4FF-A48B35D872E4Q61860441-28244378-682B-4A73-9846-D70D3C06018CQ85266331-1A4B58E9-960C-4F0C-AB3C-504B90BF66BAQ88666906-D626BE09-E08A-45DE-BFE3-E52DBB281508Q89454317-D0531A09-74D8-4E56-9C0B-3DBB18293BB9Q90393671-75296694-326A-478B-AA9A-F9C607DCA50BQ91890893-BBB9E494-6876-44D9-8CE2-9C4228AE287EQ91986061-D456958A-A224-4757-B4DA-84D5946135F6Q92578984-1F8B75AD-25DF-4337-B049-DA2D069C7EC3Q96431807-39E2D6B9-494E-47B2-BDC6-A03FA3759B68
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Malin Hultcrantz
@ast
Malin Hultcrantz
@en
Malin Hultcrantz
@es
Malin Hultcrantz
@nl
type
label
Malin Hultcrantz
@ast
Malin Hultcrantz
@en
Malin Hultcrantz
@es
Malin Hultcrantz
@nl
prefLabel
Malin Hultcrantz
@ast
Malin Hultcrantz
@en
Malin Hultcrantz
@es
Malin Hultcrantz
@nl
P106
P21
P31
P496
0000-0002-9045-6495